Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin, capecitabine, gemcitabine
hydrochloride, epirubicin hydrochloride, and docetaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving
more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known
whether cisplatin, capecitabine, and gemcitabine hydrochloride are more effective when given
together with epirubicin hydrochloride or docetaxel in treating patients with advanced or
metastatic pancreatic cancer.
PURPOSE: This randomized phase II trial is studying the side effects of giving cisplatin,
capecitabine, and gemcitabine hydrochloride together with epirubicin hydrochloride compared
with giving cisplatin, capecitabine, and gemcitabine hydrochloride together with docetaxel
and to see how well it works in treating patients with stage III or stage IV pancreatic
cancer.